Standards' Role In Biosimilarity Assessment

Why It Matters

Relying solely on reference standards could impede biosimilar approvals, affecting competition and patient access to affordable biologics.

Key Takeaways

• Standards aid analytical method validation but not biosimilarity variability.
• FDA guidance encourages standards, yet market reference diversity remains unaddressed.
• Single-point reference may misrepresent quality attributes across product batches.
• Overreliance on standards could reject acceptable biosimilar variations.
• Standards remain essential for potency assays and method calibration.

Summary

The video examines the US Pharmacopeia’s recommendation that the FDA promote the use of reference standards in biosimilarity assessments. It questions whether such standards can resolve the inherent variability seen across commercial biologic products.

The speaker acknowledges that standards are indispensable for validating analytical methods and for potency assays, serving as a fixed point of comparison. However, he argues that a single‑point reference cannot capture the full spectrum of quality attributes present in market‑available batches, leading to potential mischaracterization of biosimilar similarity.

He emphasizes, “it’s essentially a one‑point target which may not be reflecting what is out there,” warning that reliance on standards alone might reject variations that are actually acceptable. This highlights the risk of over‑filtering biosimilar candidates based on narrow criteria.

Consequently, while standards remain a critical tool, regulators must complement them with broader comparative data to ensure biosimilar approvals reflect real‑world product diversity and do not stifle market entry.

Original Description

Standards are useful tools for specific purposes, but they represent a one-point target. They do not capture the full range of variability found in reference products on the market.

During Bioprocess Online Live: Process Control's Increasing Role In Biosimilar Approval, Alvotech Managing Director and Head of R&D Strategy Cecilia Michel said they provide an important basis for potency assays; however, they lack the dexterity for comparison of a broad range of attributes.